Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
BackgroundVedolizumab is a humanized monoclonal antibody targeting the α4β7 integrin used for the treatment of ulcerative colitis. Few biomarkers related to vedolizumab response have been identified. The aim of this work was to assess whether baseline circulating CD4+ and CD8+ memory T-lymphocyte su...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.837294/full |
| _version_ | 1818203798184656896 |
|---|---|
| author | Maria Gonzalez-Vivo Maria Gonzalez-Vivo Minna K. Lund Tiirikainen Montserrat Andreu Montserrat Andreu Agnes Fernandez-Clotet Alicia López-García Alicia López-García Francisca Murciano Gonzalo Lourdes Abril Rodriguez Carmen de Jesús-Gil Ester Ruiz-Romeu Lídia Sans-de San Nicolàs Lluis F. Santamaria-Babí Lucía Márquez-Mosquera Lucía Márquez-Mosquera |
| author_facet | Maria Gonzalez-Vivo Maria Gonzalez-Vivo Minna K. Lund Tiirikainen Montserrat Andreu Montserrat Andreu Agnes Fernandez-Clotet Alicia López-García Alicia López-García Francisca Murciano Gonzalo Lourdes Abril Rodriguez Carmen de Jesús-Gil Ester Ruiz-Romeu Lídia Sans-de San Nicolàs Lluis F. Santamaria-Babí Lucía Márquez-Mosquera Lucía Márquez-Mosquera |
| author_sort | Maria Gonzalez-Vivo |
| collection | DOAJ |
| description | BackgroundVedolizumab is a humanized monoclonal antibody targeting the α4β7 integrin used for the treatment of ulcerative colitis. Few biomarkers related to vedolizumab response have been identified. The aim of this work was to assess whether baseline circulating CD4+ and CD8+ memory T-lymphocyte subpopulations could help to identify patients with response to vedolizumab treatment in ulcerative colitis.MethodsProspective pilot study in 15 patients with active ulcerative colitis and previous failure to anti-TNFα starting vedolizumab treatment. Peripheral blood samples were obtained before the first dose of vedolizumab and at week 6 and 14 of treatment. Clinical remission was defined as a Mayo Clinic partial score of ≤2 points without any concomitant dose of steroids. Biochemical remission or endoscopic improvement was defined as fecal calprotectin <250 mcg/g or Mayo endoscopic subscore ≤1.ResultsAt week 14, nine patients achieved clinical remission and eight patients achieved biochemical remission or endoscopic improvement. Patients in clinical remission presented higher baseline CD8 α4β7+ memory T cells concentration when compared with patients with no remission. In addition, patients with biochemical remission or endoscopic improvement at week 14 presented higher baseline concentration of CD8 α4β7+ memory T cells. No differences were identified according to flare severity, extent of disease or type of anti-TNFα failure. There were no significant differences regarding changes in T cell subsets during vedolizumab induction.ConclusionCD8+ α4β7+ memory T cells before starting vedolizumab therapy could be an early predictor of remission in ulcerative colitis patients and therefore help to select a subset of responders. |
| first_indexed | 2024-12-12T03:31:04Z |
| format | Article |
| id | doaj.art-4bd969502cc64794b7b0b9b1956b7e70 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-12T03:31:04Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-4bd969502cc64794b7b0b9b1956b7e702022-12-22T00:39:54ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-06-01910.3389/fmed.2022.837294837294Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative ColitisMaria Gonzalez-Vivo0Maria Gonzalez-Vivo1Minna K. Lund Tiirikainen2Montserrat Andreu3Montserrat Andreu4Agnes Fernandez-Clotet5Alicia López-García6Alicia López-García7Francisca Murciano Gonzalo8Lourdes Abril Rodriguez9Carmen de Jesús-Gil10Ester Ruiz-Romeu11Lídia Sans-de San Nicolàs12Lluis F. Santamaria-Babí13Lucía Márquez-Mosquera14Lucía Márquez-Mosquera15Department of Gastroenterology, Hospital del Mar, Barcelona, SpainIMIM (Hospital del Mar Medical Research Institute), Barcelona, SpainGrup d’Immunologia Translacional, Departament de Biologia Cel⋅lular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Científic de Barcelona (PCB), Barcelona, SpainDepartment of Gastroenterology, Hospital del Mar, Barcelona, SpainIMIM (Hospital del Mar Medical Research Institute), Barcelona, SpainDepartment of Gastroenterology, Hospital Clinic de Barcelona, Barcelona, SpainDepartment of Gastroenterology, Hospital del Mar, Barcelona, SpainIMIM (Hospital del Mar Medical Research Institute), Barcelona, SpainDepartment of Gastroenterology, Hospital del Mar, Barcelona, SpainDepartment of Gastroenterology, Hospital del Mar, Barcelona, SpainGrup d’Immunologia Translacional, Departament de Biologia Cel⋅lular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Científic de Barcelona (PCB), Barcelona, SpainGrup d’Immunologia Translacional, Departament de Biologia Cel⋅lular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Científic de Barcelona (PCB), Barcelona, SpainGrup d’Immunologia Translacional, Departament de Biologia Cel⋅lular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Científic de Barcelona (PCB), Barcelona, SpainGrup d’Immunologia Translacional, Departament de Biologia Cel⋅lular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Científic de Barcelona (PCB), Barcelona, SpainDepartment of Gastroenterology, Hospital del Mar, Barcelona, SpainIMIM (Hospital del Mar Medical Research Institute), Barcelona, SpainBackgroundVedolizumab is a humanized monoclonal antibody targeting the α4β7 integrin used for the treatment of ulcerative colitis. Few biomarkers related to vedolizumab response have been identified. The aim of this work was to assess whether baseline circulating CD4+ and CD8+ memory T-lymphocyte subpopulations could help to identify patients with response to vedolizumab treatment in ulcerative colitis.MethodsProspective pilot study in 15 patients with active ulcerative colitis and previous failure to anti-TNFα starting vedolizumab treatment. Peripheral blood samples were obtained before the first dose of vedolizumab and at week 6 and 14 of treatment. Clinical remission was defined as a Mayo Clinic partial score of ≤2 points without any concomitant dose of steroids. Biochemical remission or endoscopic improvement was defined as fecal calprotectin <250 mcg/g or Mayo endoscopic subscore ≤1.ResultsAt week 14, nine patients achieved clinical remission and eight patients achieved biochemical remission or endoscopic improvement. Patients in clinical remission presented higher baseline CD8 α4β7+ memory T cells concentration when compared with patients with no remission. In addition, patients with biochemical remission or endoscopic improvement at week 14 presented higher baseline concentration of CD8 α4β7+ memory T cells. No differences were identified according to flare severity, extent of disease or type of anti-TNFα failure. There were no significant differences regarding changes in T cell subsets during vedolizumab induction.ConclusionCD8+ α4β7+ memory T cells before starting vedolizumab therapy could be an early predictor of remission in ulcerative colitis patients and therefore help to select a subset of responders.https://www.frontiersin.org/articles/10.3389/fmed.2022.837294/fullinflammatory bowel diseaseulcerative colitisbiological therapyintegrinsT lymphocytes |
| spellingShingle | Maria Gonzalez-Vivo Maria Gonzalez-Vivo Minna K. Lund Tiirikainen Montserrat Andreu Montserrat Andreu Agnes Fernandez-Clotet Alicia López-García Alicia López-García Francisca Murciano Gonzalo Lourdes Abril Rodriguez Carmen de Jesús-Gil Ester Ruiz-Romeu Lídia Sans-de San Nicolàs Lluis F. Santamaria-Babí Lucía Márquez-Mosquera Lucía Márquez-Mosquera Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis Frontiers in Medicine inflammatory bowel disease ulcerative colitis biological therapy integrins T lymphocytes |
| title | Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis |
| title_full | Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis |
| title_fullStr | Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis |
| title_full_unstemmed | Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis |
| title_short | Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis |
| title_sort | memory t cell subpopulations as early predictors of remission to vedolizumab in ulcerative colitis |
| topic | inflammatory bowel disease ulcerative colitis biological therapy integrins T lymphocytes |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.837294/full |
| work_keys_str_mv | AT mariagonzalezvivo memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT mariagonzalezvivo memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT minnaklundtiirikainen memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT montserratandreu memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT montserratandreu memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT agnesfernandezclotet memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT alicialopezgarcia memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT alicialopezgarcia memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT franciscamurcianogonzalo memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT lourdesabrilrodriguez memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT carmendejesusgil memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT esterruizromeu memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT lidiasansdesannicolas memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT lluisfsantamariababi memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT luciamarquezmosquera memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis AT luciamarquezmosquera memorytcellsubpopulationsasearlypredictorsofremissiontovedolizumabinulcerativecolitis |